Module 3 2019

Reimbursement Issues ➢ Drug budget under increasing pressure o Formularies to prohibit availability of all drugs in the same class o ‘Value for Money’ (NICE etc) assessments prevent or limit use of perceived expensive new drugs ➢ Orkambi (ivacaftor + lumacaftor) for F508del Cystic

Fibrosis treatment (~ 4,000 UK patients) o US price £207,000 ($272,000) per patient year

o Initial UK price £105,000 per patient year rejected by NHS o Confidential commercial deal struck to allow NHS use (could be as low as £20,000 per patient year to match generic from Argentina)

4